Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.
Eli Lilly expects its experimental weightlosspill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and NovoNordisk, which dominate the ...